FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1548074080> ?p ?o ?g. }

• W1548074080 endingPage "1171" @default.
• W1548074080 startingPage "1163" @default.
• W1548074080 abstract "Adenosine deaminase (ADA) deficiency and its biochemical consequences cause severe combined immunodeficiency (SCID). Treatment strategies, designed to correct the biochemical abnormalities, include transplantation of matched bone marrow or haploidentical bone marrow stem cells, repeated partial exchange transfusions with frozen irradiated human red blood cells (RBC), or weekly injection of polyethylene glycol-modified bovine ADA (PEG-ADA). To evaluate the effect of these therapeutic options, we studied in vitro T-cell function and in vivo antibody responses to the T-cell-dependent neoantigen, bacteriophage phi X174, in 10 children with ADA-deficient SCID. In untreated patients, T-cell function was severely depressed, and only minute amounts of antibacteriophage antibody were produced. Transplantation of bone marrow from a matched sibling (one patient) or a phenotypically matched parent (one patient) resulted in a stable graft, normal T-cell function, and substantial but subnormal antibody titers to bacteriophage, with reduced memory and impaired switch from IgM to IgG. Patients receiving T-cell-depleted haploidentical bone marrow stem cells had markedly depressed antibody responses for as long as 3 years posttransplantation, despite rapidly improving T-cell function that became normal in two of four patients. Two methods of enzyme replacement were explored. During treatment with human RBC transfusions, antibody responses to bacteriophage were as severely depressed as in untreated ADA-deficient patients. Treatment with weekly injections of PEG-ADA resulted in normalization of T-cell numbers in all four patients, normal or near-normal T-cell function in two, and mildly but variably improved T-cell function in the other two patients. Quantitatively and qualitatively normal antibody responses to bacteriophage were observed in three of four patients. Assessment of antibody responses to immunization with bacteriophage phi X174 is a useful method to monitor humoral immune function in treated ADA- deficient patients and can be used to estimate when intravenous immunoglobulin (IVIG) prophylaxis may be safely discontinued." @default.
• W1548074080 created "2016-06-24" @default.
• W1548074080 creator A5004759130 @default.
• W1548074080 creator A5015108059 @default.
• W1548074080 creator A5022699593 @default.
• W1548074080 creator A5037161551 @default.
• W1548074080 creator A5047080103 @default.
• W1548074080 creator A5050737776 @default.
• W1548074080 creator A5062237763 @default.
• W1548074080 creator A5068761013 @default.
• W1548074080 date "1992-09-01" @default.
• W1548074080 modified "2023-10-16" @default.
• W1548074080 title "Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency" @default.
• W1548074080 cites W1554699584 @default.
• W1548074080 cites W1577028136 @default.
• W1548074080 cites W1970415463 @default.
• W1548074080 cites W1999516176 @default.
• W1548074080 cites W2000702466 @default.
• W1548074080 cites W2005101707 @default.
• W1548074080 cites W2032848431 @default.
• W1548074080 cites W2045194355 @default.
• W1548074080 cites W2067780440 @default.
• W1548074080 cites W2069827333 @default.
• W1548074080 cites W2075851121 @default.
• W1548074080 cites W2079752228 @default.
• W1548074080 cites W2081604928 @default.
• W1548074080 cites W2088274041 @default.
• W1548074080 cites W2143803600 @default.
• W1548074080 cites W2156374047 @default.
• W1548074080 cites W2336924892 @default.
• W1548074080 cites W2336950812 @default.
• W1548074080 cites W2407956967 @default.
• W1548074080 cites W2466050546 @default.
• W1548074080 doi "https://doi.org/10.1182/blood.v80.5.1163.bloodjournal8051163" @default.
• W1548074080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1387561" @default.
• W1548074080 hasPublicationYear "1992" @default.
• W1548074080 type Work @default.
• W1548074080 sameAs 1548074080 @default.
• W1548074080 citedByCount "28" @default.
• W1548074080 countsByYear W15480740802012 @default.
• W1548074080 countsByYear W15480740802014 @default.
• W1548074080 countsByYear W15480740802015 @default.
• W1548074080 countsByYear W15480740802016 @default.
• W1548074080 countsByYear W15480740802017 @default.
• W1548074080 countsByYear W15480740802022 @default.
• W1548074080 crossrefType "journal-article" @default.
• W1548074080 hasAuthorship W1548074080A5004759130 @default.
• W1548074080 hasAuthorship W1548074080A5015108059 @default.
• W1548074080 hasAuthorship W1548074080A5022699593 @default.
• W1548074080 hasAuthorship W1548074080A5037161551 @default.
• W1548074080 hasAuthorship W1548074080A5047080103 @default.
• W1548074080 hasAuthorship W1548074080A5050737776 @default.
• W1548074080 hasAuthorship W1548074080A5062237763 @default.
• W1548074080 hasAuthorship W1548074080A5068761013 @default.
• W1548074080 hasBestOaLocation W15480740801 @default.
• W1548074080 hasConcept C126322002 @default.
• W1548074080 hasConcept C150903083 @default.
• W1548074080 hasConcept C159654299 @default.
• W1548074080 hasConcept C203014093 @default.
• W1548074080 hasConcept C207001950 @default.
• W1548074080 hasConcept C2776090121 @default.
• W1548074080 hasConcept C2776991684 @default.
• W1548074080 hasConcept C2779468541 @default.
• W1548074080 hasConcept C2780007613 @default.
• W1548074080 hasConcept C2781161190 @default.
• W1548074080 hasConcept C2911091166 @default.
• W1548074080 hasConcept C34628245 @default.
• W1548074080 hasConcept C71924100 @default.
• W1548074080 hasConcept C86803240 @default.
• W1548074080 hasConcept C8891405 @default.
• W1548074080 hasConceptScore W1548074080C126322002 @default.
• W1548074080 hasConceptScore W1548074080C150903083 @default.
• W1548074080 hasConceptScore W1548074080C159654299 @default.
• W1548074080 hasConceptScore W1548074080C203014093 @default.
• W1548074080 hasConceptScore W1548074080C207001950 @default.
• W1548074080 hasConceptScore W1548074080C2776090121 @default.
• W1548074080 hasConceptScore W1548074080C2776991684 @default.
• W1548074080 hasConceptScore W1548074080C2779468541 @default.
• W1548074080 hasConceptScore W1548074080C2780007613 @default.
• W1548074080 hasConceptScore W1548074080C2781161190 @default.
• W1548074080 hasConceptScore W1548074080C2911091166 @default.
• W1548074080 hasConceptScore W1548074080C34628245 @default.
• W1548074080 hasConceptScore W1548074080C71924100 @default.
• W1548074080 hasConceptScore W1548074080C86803240 @default.
• W1548074080 hasConceptScore W1548074080C8891405 @default.
• W1548074080 hasIssue "5" @default.
• W1548074080 hasLocation W15480740801 @default.
• W1548074080 hasOpenAccess W1548074080 @default.
• W1548074080 hasPrimaryLocation W15480740801 @default.
• W1548074080 hasRelatedWork W1666496871 @default.
• W1548074080 hasRelatedWork W1967023974 @default.
• W1548074080 hasRelatedWork W2002563756 @default.
• W1548074080 hasRelatedWork W2012738976 @default.
• W1548074080 hasRelatedWork W2059550336 @default.
• W1548074080 hasRelatedWork W2073257205 @default.
• W1548074080 hasRelatedWork W2095073287 @default.
• W1548074080 hasRelatedWork W2159106727 @default.
• W1548074080 hasRelatedWork W2422849325 @default.

• next